Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug

Impact · against what's priced in

Pfizer receives a significant off-balance-sheet funding boost to preserve margins while developing its weight-loss candidate. The $1.5 billion contribution from Blackstone reduces immediate R&D risk and capital expenditure through 2028.

PFE+0.60

No priced-in read yet

In context

Blackstone's $1.5 billion commitment to cover development costs for berobenatide through 2028 protects Pfizer's operating margins by shifting R&D spend off-balance-sheet.

Read from the article alone

• healthcare
• biotech
• pharmaceuticals
• PFE
• blackstone
• drug development
• investment
• pfizer

Search tags